ABSTRACT & COMMENTARY

Androgen Deprivation Therapy and SARS-CoV-2

Name: Relias Media
Price range: $

July 30, 2020

Cancer patients are at a higher risk of contracting SARS-CoV-2 vs. non-cancer patients. However, prostate cancer patients who received androgen deprivation therapy seem to be partially protected from such infections.

Issue Date: July 30, 2020

Table of Contents

Financial Disclosure: Internal Medicine Alert’s Physician Editor Stephen Brunton, MD, is a retained consultant for Abbott Diabetes, Acadia, AstraZeneca, and Boehringer Ingelheim; and he serves on the speakers bureau of AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, and Novo Nordisk. Peer Reviewer Gerald Roberts, MD; Editor Jonathan Springston; Editor Jason Schneider; Editorial Group Manager Leslie Coplin; and Accreditations Director Amy M. Johnson, MSN, RN, CPN, report no financial relationships relevant to this field of study.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements